Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
SkyePharma (LSE:SKP), a pharmaceutical company specialising in the development of inhaled products and drug delivery technologies, announced today that it has signed a second agreement to conduct a feasibility study with RespiVert, a small molecule drug discovery company specializing in respiratory disorders. This agreement comes on the heels of the successful completion of a similar programme over the past fifteen months for another Respivert compound.
This feasibility study will seek to develop a new dry powder inhaler for patients afflicted with severe respiratory ailments, such as chronic obstructive pulmonary disease, and severe asthma. Shares of SkyePharma were up 13% to 37.75p as of 10:46 GMT.
Executive Comments
SkyePharma CEO Peter Grant:
“We are pleased that the excellent progress with the first feasibility project has led to this follow-on project, and we look forward to collaborating further with RespiVert to develop important new products for patients suffering from respiratory diseases. Over the past 20 years, SkyePharma has established world-class respiratory development expertise covering both metered dose and dry powder inhalation products.”
Company Spotlight
SkyePharma is a developer of inhaled products and drug delivery technologies whose products are marketed throughout the world by leading pharmaceutical companies. The company has eleven approved products in the areas of oral and topical delivery and licence and revenue-generating products in inhalation and injectable technologies.
References
↑ About SkyePharma
↑ About Respivert
↑ SkyePharma Respivert Contract
